David C. Flyer

2.8k total citations
45 papers, 1.9k citations indexed

About

David C. Flyer is a scholar working on Infectious Diseases, Immunology and Epidemiology. According to data from OpenAlex, David C. Flyer has authored 45 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Infectious Diseases, 17 papers in Immunology and 16 papers in Epidemiology. Recurrent topics in David C. Flyer's work include Virus-based gene therapy research (11 papers), Immunotherapy and Immune Responses (9 papers) and Respiratory viral infections research (8 papers). David C. Flyer is often cited by papers focused on Virus-based gene therapy research (11 papers), Immunotherapy and Immune Responses (9 papers) and Respiratory viral infections research (8 papers). David C. Flyer collaborates with scholars based in United States, Germany and China. David C. Flyer's co-authors include Gregory M. Glenn, Gale Smith, Douglas V. Faller, Satvir S. Tevethia, Michael J. Massare, Steven J. Burakoff, Ye V. Liu, Hanxin Lu, Richard A. Flavell and John D. Fraser and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and The Journal of Immunology.

In The Last Decade

David C. Flyer

45 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David C. Flyer United States 24 795 714 659 336 192 45 1.9k
Julie Furze United Kingdom 23 783 1.0× 737 1.0× 1.3k 1.9× 464 1.4× 239 1.2× 27 2.2k
Linda S. Klavinskis United Kingdom 27 500 0.6× 1.5k 2.1× 580 0.9× 499 1.5× 235 1.2× 56 2.4k
Michael Vajdy United States 28 527 0.7× 1.2k 1.6× 543 0.8× 513 1.5× 160 0.8× 61 2.1k
Gary Van Nest United States 34 569 0.7× 2.0k 2.8× 1.4k 2.2× 764 2.3× 140 0.7× 48 3.9k
Kai Schulze Germany 29 553 0.7× 781 1.1× 432 0.7× 567 1.7× 154 0.8× 71 1.9k
Virgil E.J.C. Schijns Netherlands 27 327 0.4× 1.1k 1.6× 453 0.7× 483 1.4× 99 0.5× 59 2.0k
Frédéric Martinon France 21 449 0.6× 986 1.4× 324 0.5× 684 2.0× 145 0.8× 54 1.8k
Robert J. Hogan United States 27 1.3k 1.6× 2.0k 2.8× 1.4k 2.1× 799 2.4× 230 1.2× 65 3.9k
Hanné Andersen United States 20 1.3k 1.6× 744 1.0× 1.1k 1.6× 548 1.6× 165 0.9× 49 2.5k
Michele A. Kutzler United States 25 688 0.9× 1.3k 1.9× 583 0.9× 871 2.6× 174 0.9× 61 2.5k

Countries citing papers authored by David C. Flyer

Since Specialization
Citations

This map shows the geographic impact of David C. Flyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David C. Flyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David C. Flyer more than expected).

Fields of papers citing papers by David C. Flyer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David C. Flyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David C. Flyer. The network helps show where David C. Flyer may publish in the future.

Co-authorship network of co-authors of David C. Flyer

This figure shows the co-authorship network connecting the top 25 collaborators of David C. Flyer. A scholar is included among the top collaborators of David C. Flyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David C. Flyer. David C. Flyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Welliver, Charles, James F. Papin, Jing-Hui Tian, et al.. (2019). Maternal immunization with RSV fusion glycoprotein vaccine and substantial protection of neonatal baboons against respiratory syncytial virus pulmonary challenge. Vaccine. 38(5). 1258–1270. 9 indexed citations
2.
Tian, Jing-Hui, Gregory M. Glenn, David C. Flyer, et al.. (2017). Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models. Vaccine. 35(33). 4079–4087. 13 indexed citations
3.
Coleman, Christopher M., Thiagarajan Venkataraman, Ye V. Liu, et al.. (2017). MERS-CoV spike nanoparticles protect mice from MERS-CoV infection. Vaccine. 35(12). 1586–1589. 76 indexed citations
4.
Smith, Gale, Xiangjie Sun, Yaohui Bai, et al.. (2017). Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets. Virology. 509. 90–97. 36 indexed citations
5.
6.
Bengtsson, Karin Lövgren, Haifeng Song, Linda Stertman, et al.. (2016). Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice. Vaccine. 34(16). 1927–1935. 94 indexed citations
7.
Glenn, Gregory M., Louis Fries, D. Nigel Thomas, et al.. (2015). A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age. The Journal of Infectious Diseases. 213(3). 411–422. 115 indexed citations
8.
Glenn, Gregory M., Louis Fries, Gale Smith, et al.. (2015). Modeling maternal fetal RSV F vaccine induced antibody transfer in guinea pigs. Vaccine. 33(47). 6488–6492. 21 indexed citations
9.
Coleman, Christopher M., Ye V. Liu, Justin Taylor, et al.. (2014). Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine. 32(26). 3169–3174. 226 indexed citations
10.
11.
Ellingsworth, Larry, et al.. (2008). Controlled, single-step, stratum corneum disruption as a pretreatment for immunization via a patch. Vaccine. 26(22). 2782–2787. 44 indexed citations
12.
McKenzie, Robin, A. Louis Bourgeois, Sarah A. Frech, et al.. (2007). Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): Protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine. 25(18). 3684–3691. 93 indexed citations
13.
Flyer, David C.. (1993). An Overview of T-Cell Biology. American Journal of Contact Dermatitis. 4(2). 98–100. 1 indexed citations
14.
Jiang, Dong & David C. Flyer. (1992). Immune response to Moloney murine leukemia virus nonviral, tumor-associated antigens fails to provide in vivo tumor protection. The Journal of Immunology. 148(3). 974–980. 6 indexed citations
15.
Faller, D V, et al.. (1988). Mechanism of induction of class I major histocompatibility antigen expression by murine leukemia virus. Journal of Cellular Biochemistry. 36(3). 297–309. 14 indexed citations
16.
Flyer, David C., et al.. (1987). Murine Retroviruses Control Class I Major Histocompatibility Antigen Gene Expression via a trans Effect at the Transcriptional Level. Molecular and Cellular Biology. 7(7). 2406–2415. 12 indexed citations
17.
Flyer, David C., Steven J. Burakoff, & Douglas V. Faller. (1985). Retrovirus-induced changes in major histocompatibility complex antigen expression influence susceptibility to lysis by cytotoxic T lymphocytes.. The Journal of Immunology. 135(4). 2287–2292. 86 indexed citations
18.
Flyer, David C., Steven J. Burakoff, & Douglas V. Faller. (1985). Expression and CTL recognition of cloned subgenomic fragments of moloney murine leukemia virus in murine cells. PubMed. 4(2). 168–172. 5 indexed citations
19.
Flyer, David C., Ronald Anderson, & Satvir S. Tevethia. (1982). Lyt phenotype of H-2b CTL effectors and precursors specific for the SV40 transplantation rejection antigen.. The Journal of Immunology. 129(6). 2368–2371. 15 indexed citations
20.
Tevethia, Satvir S., David C. Flyer, & Robert Tjian. (1980). Biology of simian virus 40 (SV40) transplantation antigen (TrAg). Virology. 107(1). 13–23. 85 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Julie Furze Breakdown of academic impact, for papers by Linda S. Klavinskis Breakdown of academic impact, for papers by Michael Vajdy Breakdown of academic impact, for papers by Gary Van Nest Breakdown of academic impact, for papers by Kai Schulze Breakdown of academic impact, for papers by Virgil E.J.C. Schijns Breakdown of academic impact, for papers by Frédéric Martinon Breakdown of academic impact, for papers by Robert J. Hogan Breakdown of academic impact, for papers by Hanné Andersen Breakdown of academic impact, for papers by Michele A. Kutzler
Rankless by CCL
2026